In vitro and in vivo study of ROC-325 and its analogs in live sars-COV-2 models
Ended Purchase Order Awarded Last action
- Contract number
- 75N95022P00510
- Awardee
-
Texas Biomedical Research Institute UEI J4EYPCJDQ1H6
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $99,991
Award facts
- Opportunity
-
- In vitro and in vivo study of ROC-325 and its analogs in live SARS-CoV-2 models in support of COVID 19 research. Solicitation · 75N95022Q00477 · Posted Aug 5, 2022
- Contract value 100% obligated
- $99,990.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Antonio, TX 78227, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $1 | |
| Original award | $99,990 |
About this award
This is a firm fixed-price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to the Texas Biomedical Research Institute, also known as the Southwest Foundation for Biomedical Research. The $99,990.60 contract is for in vitro and in vivo studies of the compound ROC-325 and its analogs against live SARS-CoV-2 models, including the WA-1, Delta, and Omicron variants. The work will assess the efficacy of ROC-325, both as a single treatment and in combination with other therapeutics, to address the potential for mutation-acquired resistance. The contract has a 12-month period of performance, with the in vitro studies occurring in the first 3-6 months and the in vivo studies in the subsequent 3-6 months. There is no set-aside designation for this non-competitive commercial item acquisition, which is being awarded based on the Texas Biomedical Research Institute's specialized expertise in handling SARS-CoV-2 and conducting related preclinical research.
Quick answers
Who was awarded contract 75N95022P00510?
75N95022P00510 was awarded to Texas Biomedical Research Institute by National Institute on Drug Abuse (National Institutes of Health) on August 30, 2022.
How much is contract 75N95022P00510 worth?
The government has obligated $99,991 on 75N95022P00510.
Which agency awarded contract 75N95022P00510?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95022P00510, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95022P00510 competed?
The extent of competition for 75N95022P00510 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award